HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Ticagrelor Reduces Events in Diabetics with Prior MI

    All studies on diabetics have shown these patients have higher risk rates of thrombotic events. This study...
solaci -
Learn More
Antiplatelet

DAPT after PCI with EES: 6 or 12 Months?

Original Title: 6-Month versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation. The IVUS-XPL Randomized Clinical Trial. Reference:...
solaci -
Learn More
Antiplatelet

Does Ticagrelor Reduce Events in Peripheral Artery Disease?

Original Title: Ticagrelor for Prevention of Ischemic Events after Myocardial Infarction in Patients with Peripheral Artery Disease. Reference:...
solaci -
Learn More
Acute coronary syndromes

Metoprolol before primary PCI doesn’t reduce infarction size

Original Title: Early Intravenous Beta-Blockers in Patients with ST-Segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention. Reference:...
solaci -
Learn More
Antiplatelet

STEMI: Best P2Y12 inhibitor according to network meta-analysis

Original Title: Optimal P2Y12 inhibitor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention:...
solaci -
Learn More
Antiplatelet

Effects of switching from prasugrel to ticagrelor in patients with ACS

Original Title: Pharmacodynamic Effects of Switching from Prasugrel to Ticagrelor Results of the Prospective, Randomized SWAP-3 Study Reference:...
solaci -
Learn More
Acute coronary syndromes

Optimal Duration of Dual Antiplatelet Therapy: New ACC-AHA Guidelines

Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary...
solaci -
Learn More
Antithrombotic Anticoagulants

Vorapaxar in Acute Limb Ischemia

Original Title: Acute Limb Ischemia and Outcomes With Vorapaxar in Patients with Peripheral Artery Disease: Results From...
solaci -
Learn More